original articlesthoracic tumorsTargeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
thoracic tumors
Under an Elsevier user license
open archive
Key words
dacomitinib
HER2 mutations
HER2 amplification
lung cancers
tyrosine kinase inhibitors
Cited by (0)
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.